Computational screening of chalcones acting against topoisomerase IIα and their cytotoxicity towards cancer cell lines

Kanyani Sangpheak, Monika Mueller, Nitchakan Darai, Peter Wolschann, Chonticha Suwattanasophon, Ritbey Ruga, Warinthon Chavasiri, Supaporn Seetahae, Kiattawee Choowongkomon, Nawee Kungwan, Chompoonut Rungnim and Thanyada Rungrotmongkol

ABSTRACT
Targeted cancer therapy has become one of the high potential cancer treatments. Human topoisomerase II (hTopoII), which catalyzes the cleavage and rejoining of double-stranded DNA, is an important molecular target for the development of novel cancer therapeutics. In order to diversify the pharmacological activity of chalcones and to extend the scaffold of topoisomerase inhibitors, a series of chalcones was screened against hTopoIIAb generated by computational techniques, and subsequently tested for their in vitro cytotoxicity. From the experimental IC50 values, chalcone 3d showed a high cytotoxicity with an IC50 value of 10.8, 3.2 and 21.1 µM against the HT-1376, HeLa and MCF-7 cancer-derived cell lines, respectively, and also exhibited an inhibitory activity against hTopoIIAB-ATPase that was better than the known inhibitor, salvicine. The observed ligand–protein interactions from a molecular dynamics study affirmed that 3d strongly interacts with the ATP-binding pocket residues. Altogether, the newly synthesised chalcone 3d has a high potential to serve as a lead compound for topoisomerase inhibitors.

1. Introduction
Nowadays, cancer is one of the most serious groups of diseases in the world, with the number of deaths attributed to cancers being about 8.8 million in 2015 (World Health Organization, 2017)1. Chemotherapy is currently a highly effective cancer treatment. However, most chemotherapeutic agents give severe side effects with limited selectivity against various cancer cells. Hence, development of anti-cancer drugs with no or less side effects and a high selectivity is of prime concern2. Targeted cancer therapy, in which the drugs are used to specifically block the growth of cancer by interfering with molecular targets and consequently causing less damage to normal cells, has become one of the high potential cancer treatments. Several kinds of molecular targets have been focused on in recent years, including human topoisomerase II (hTopoII). This enzyme catalyzes the cleavage and rejoining of double-stranded DNA and so it is essential in several vital processes, such as replication, transcription, chromosome separation and segregation3. Generally, hTopoII exists in two homologous structures but in different isoforms, hTopoIIα and hTopoIIβ. The hTopoIIα isoform shows a low expression level in the G cell cycle phase but an increased concentration in the S and G2/M phases compared to normal cells, whilst hTopoIIβ does not change its concentration during the cell cycle4. Since hTopoIIα is highly overexpressed in proliferating cancer cells5, it has gained attention from many researchers who are developing new anti-cancer drugs.

There are two important motifs for drugs targeting hTopoIIα, namely the ATPase domain (Figure 1(A)) and the DNA-binding core (Figure 1(B)). The hTopoIIα inhibitors can be divided into two categories, hTopoIIα poisons and hTopoIIα catalytic inhibitors. For hTopoIIα poisons (etoposide, doxorubicin, anthracyclines and mitoxantrone), they are clinically active agents that generate a high level of hTopoII–DNA covalent complexes by stimulating cleavage of the G-segment and blocking relegation of DNA5. On the other hand, hTopoIIα catalytic agents (ICRF-187, novobiocin, merbarone and salvicine) affect the catalytic cycle of hTopoIIα by elimination of the enzymatic activity6–10. Although these different catalytic agents share the same effect, they interact with hTopoIIα at different binding sites. For example, the ICRF-187 binding pocket is located in the middle of the primary dimer interface9, while merbarone acts by blocking the DNA cleavage reaction of hTopoIIα. The merbarone-binding site possesses an interaction...
domain overlapping with that of etoposide\textsuperscript{11-13}. Salvicine, a derivative of diterpenoid quinones isolated from the traditional Chinese medicinal plant \textit{Salvia prioris}\textsuperscript{10,14}, targets the ATPase domain\textsuperscript{15-17}.

The polyphenolic compounds, chalcones or 1,3-diphenyl-2-propane-1-ones, are precursors for flavonoids and isoflavonoids. They consist of two aromatic rings connected by an \(\alpha,\beta\)-unsaturated carbon atom chain. Chalcones are naturally found in several plants, such as \textit{Piper methysticum}\textsuperscript{18} and members of the \textit{Glycyrrhiza}\textsuperscript{19} and \textit{Angelica}\textsuperscript{20} genera. Natural and synthetic derivatives of chalcones have been reported to exert several biological activities, including anti-fungal, anti-microbial, anti-protozoal, anti-viral, anti-malarial, anti-inflammatory and antioxidant effects\textsuperscript{21-24}. In addition, they have been shown to have cytotoxic activities against various cancer cell lines, including breast (MCF-7)\textsuperscript{25}, ovary (A2780)\textsuperscript{28}, lung (A549)\textsuperscript{27,29}, colon (SW480)\textsuperscript{30}, liver (HepG2)\textsuperscript{31,32} and cervical (HeLa)\textsuperscript{33} cancer cell lines.

Chalcones have attracted attention because of their promising therapeutic effects, since they are able to target multiple cellular molecules, such as MDM2/p53, tubulin, proteasome, NF-\(\kappa\)B, TRIAL/death receptors and mitochondria-mediated apoptotic pathways, cell cycle, STAT3, AP-1, NFR2, AR, ER, PPAR-\(\gamma\), \(\beta\)-catenin/Wnt\textsuperscript{34} and especially hTopoII\textsuperscript{\textsuperscript{18,23,35-37}}. Moreover, epipodophyllotoxin–chalcone hybrids exhibited an enhanced \textit{in vitro} cytotoxicity and higher topoisomerase II inhibitory efficiency than etoposide\textsuperscript{38}. A series of chalcone-triazole derivatives presented a promising anti-cancer activity against the A-549 cell line and showed high binding affinities towards DNA topoisomerase II and \(\alpha\)-glucosidase targets\textsuperscript{39}. Moreover, the novel \textit{bis}-fluorquinolone chalcone-like derivatives were found to inhibit both hTopoII and tyrosine kinase\textsuperscript{40}. Recently, a series of \textit{2'}- and \textit{4'}-aminochalcones were found to inhibit the growth of a canine malignant histiocytic cell line (DH82) and the transcription of the hTopoII and TP53 genes\textsuperscript{41}. In the present study, in order to find new potential anti-cancer agents against hTopoII, the new 47 chalcone derivatives were designed (Figure 2) and then screened in \textit{silico} using a molecular docking approach. The potent chalcones with a more favorable interaction energy than that of the known hTopoII inhibitors were then synthesised and tested for their \textit{in vitro} cytotoxicity towards three cell lines derived from urinary bladder (HT-1376), cervical (HeLa) and breast (MCF-7) cancers. Then, all-atom molecular dynamics (MD) simulations were performed to investigate the structure and dynamics properties as well as the ligand–target interactions between the most potent chalcone and hTopoII.

**Figure 1.** The hTopoII\textsubscript{\textit{\textalpha}} structures used in the docking study. (A) The ATPase domain of hTopoII\textsubscript{\textit{\textalpha}} with the \(5'-\)adenylyl-\(\beta,\gamma\)-imidodiphosphate, AMP-PNP (space filling model), in the ATP-binding pocket, where the GHKL and transducer domains are shown in green and pink (PDB code: 1ZXM). (B) The hTopoII\textsubscript{\textit{\textalpha}}/DNA/etoposide ternary complex (PDB code: 3QX3).

### 2. Methodology

#### 2.1. Material

Human urinary bladder, cervical and breast cancer-derived cell lines (HT-1376, HeLa and MCF-7, respectively) were obtained from the American Type Culture Collection (ATCC), Manassas, VA. Dulbecco’s modified eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin–streptomycin (Pen–Strep) and trypsin were purchased from Life Technologies (Carlsbad, CA). Thiazolyl blue (MTT), dimethyl sulphoxide (DMSO), sodium dodecyl sulphate (SDS) and phosphate-buffered saline (PBS) were purchased from Sigma-Aldrich (Darmstadt, Germany). Salvicine was purchased from Chemfaces (Wuhan, P.R. China). The purity of the compound was more than 98.0%. All other chemicals and solvents used were of analytical grade. Plasmid pET28b-hTopoII-ATPase was gifted from Dr. Nonlawat Boonyalai. ADP-Glo™ Kinase Assay kit was purchased from Promega (Madison, WI). All solvents used for the synthesis were purified prior to use by standard methodologies. The reagents used for synthesis were purchased from Sigma-Aldrich, Merck or TCI chemical companies and were used without further purification.

#### 2.2. Computational methods

##### 2.2.1. Molecular docking

Due to the possibility of the inhibition of two motifs of the hTopoII\textsubscript{\textit{\textalpha}} (ATP-binding site in the ATPase domain and the etoposide-binding pocket in the hTopoII\textsubscript{\textit{\textalpha}}/DNA complex), the predicting mode of the inhibitory activity of chalcones on both sites was studied by molecular docking using the CDocker module of Accelrys Discovery Studio 3.0 (Accelrys Inc, San Diego, CA, USA) as previously reported\textsuperscript{42}. The starting structures of the 47 designed chalcone derivatives were built by the GaussView program\textsuperscript{43}, while those of salvicine and etoposide were taken from the ZINC database\textsuperscript{44}. To validate the docking method, the co-crystallised ligands were initially docked into the binding pocket with 100 independent runs, i.e. docking of AMP-PNP into the ATP-binding site of the hTopoII\textsubscript{\textit{\textalpha}} ATPase domain (1ZXM.pdb), and etoposide into its binding pocket of the hTopoII\textsubscript{\textit{\textalpha}}/DNA complex (3QX3.pdb). The position of docked ligands did not differ significantly from the crystallised conformation ligands (RMSD = 0.80 Å for AMP-PNP and 0.44 Å for etoposide) and so the 47 chalcones were then separately docked into both sites, while salvicine (used as the
reference compound at the ATPase domain) was only docked into the ATP-binding site. The chalcones with predicted interaction energies towards hTopoII that were more favorable than those of the known inhibitors were synthesised and their in vitro cytotoxicity against the three cancer cell lines was tested (see Section 2.3.3).

2.2.2. MD simulation
All-atom MD simulations under a periodic boundary condition were performed on the most potent chalcone selected from the in vitro cytotoxicity study (Section 2.3.3) in complex with hTopoI in aqueous solution, following the previously reported MD study on the binding of mansonone G to hTopoI. The partial charges of the ligand were prepared according to standard procedures. The ligand was optimised with ab initio calculation using the HF/6-31G* method in the Gaussian09 program. The electrostatic potential (ESP) charges of the ligand were calculated using the same level of theory, and then the restrained ESP (RESP) charges were obtained by the charge fitting procedure using the antechamber module in the AMBER 14 package program. The general AMBER force field (GAFF) and AMBER ff03 force field were applied for the ligand and protein, respectively. The protonation states of all ionizable amino acids were determined using PROPKA 3.1. To complex was solvated by TIP3P water molecules within 12 Å around the system surface. Chloride ions were introduced to neutralise the total positive charge of the chalcone/hTopoI complex.

To remove the bad contacts and steric hindrances, the added hydrogen atoms were minimised with 1000 steps of steepest descents (SD) followed by 2000 steps of conjugated gradients (CG) using the Sander module in AMBER 14. The water molecules and ions were then minimised with 500 steps of SD followed by 500 steps of CG, while a 500 kcal/mol Å² force constant was used to restrain hTopoI. The whole system was then fully minimised with 1000 steps of SD and CG. All covalent bonds involving hydrogen atoms were constrained by the SHAKE algorithm (Amber, San Francisco, CA). The long-range electrostatic interactions were calculated according to the Particle Mesh Ewald (PME) approach with a cutoff distance of 12 Å for non-bonded interactions.

Figure 2. Chemical structure of the 47 designed chalcones from six different groups.
The system was heated to 310 K for 100 ps and then simulated at the same temperature for 80 ns in the NPT ensemble using a time step of 2 fs. The MD trajectories in the production phase were taken for analysis in terms of the per-residue decomposition free energy and intermolecular hydrogen bonds (H-bonds) between the ligand and hTopoIIα using the MM/PBSA.py and cpptraj modules, respectively. The percentage of H-bond occupation was calculated using the two criteria of: (i) the distance between proton donor (HD) and acceptor (HA) atoms ≤ 3.5 Å and (ii) the angle of HD-H...HA > 120°.

2.3. Experimental approach

2.3.1. Synthesis of chalcone derivatives

The three selected chalcones (3c, 3d and 3f) were synthesised by Claisen–Schmidt condensation with some modifications between selected acetophenones and benzaldehydes under a basic condition, according to the procedures described by Cabrera58. The target products were purified by column chromatography and their structures were elucidated by NMR spectroscopy.

2.3.2. Cell culture and sample preparation

Stock cultures of HT-1376, HeLa and MCF-7 cell lines were grown in T-75 flasks in complete medium [CM; DMEM, 10% (v/v) FBS and 1% (v/v) Pen–Strep] at 37 °C under 5% (v/v) CO2. They were sub-cultured once a week, for HeLa and MCF-7 cells at a 1:100 ratio and for HT-1376 at 1:20 ratio by washing with PBS and then the cells were detached with trypsin. The 10−1 M stock solution of each respective chalcone derivative was prepared in 100% DMSO.

2.3.3. Cytotoxicity assay

The cytotoxicity of the chalcones and salvicine was measured according to a published method57 with some modifications. The cell viabilities of three cancer cell lines (HT-1376, HeLa and MCF-7) exposed to the screened chalcone derivatives were evaluated by the MTT assay. The cell suspension (100 μL) was seeded into 96-well plates at a density of 2 × 104 cells/well and then incubated for 24 h under normal culture conditions before the addition of the respective test compound at various concentrations [100, 50, 25, 12.5 and 0 (control) μM] and incubated for another 24 h. Then, 10 μL of fresh MTT solution (5 mg/mL) was added to each well and incubated at 37 °C for 2 h, before the reaction was stopped by adding 100 μL of DMSO. The absorbance was measured at 570 nm with correction for background at 690 nm using a microplate spectrophotometer system (Infinite M200 micro-plate reader, Tecoan, Mannendorf, Switzerland). The amount of the colored product is assumed to be directly proportional to the number of viable cells. Each experiment was performed in triplicate and repeated three times. The percentage cell viability in each compound was calculated relative to the control, and the IC50 values were determined in comparison with untreated controls using the Table Curve 2D program version 5.01 (Systat, San Jose, CA).

2.3.4. Expression and enrichment of the recombinant (r)hTopoIIα ATPase domain

Expression and enrichment of the rhTopoIIα ATPase domain was modified from that reported58. The expression plasmid pET28b-hTopoIIα-ATPase was transformed into Escherichia coli BL21 (DE3) cells and a transformant colony was selected for large-scale protein expression and grown at 37 °C to an optical density at 600 nm of ~0.6 in LB broth (2L) containing 50 μg/mL kanamycin. Protein expression was then induced by adding 0.5 mM IPTG at 30 °C for 5 h. The cells were harvested by centrifugation at 6000×g, 4 °C and resuspended in lysis buffer [50 mM Tris–Cl pH 8, 0.5 M NaCl, 5 mM imidazole, 0.5% (v/v) Triton X-100, 1 mM PMSF] and lysed by sonication. After clarification by centrifugation (as above) the supernatant was harvested, and the rhTopoIIα-ATPase enriched for using HisTrap Chelating HP and Resource S column chromatography, eluting in exchange buffer [50 mM Tris pH 7.5, 50 mM NaCl, 5% (v/v) glycerol, 50 mM KCl, 5 mM MgCl2] from a PD-10 desalting column. The enriched protein was analyzed by 12% sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and stained by Coomassie blue.

2.3.5. ATPase assay

The inhibitory activities of salvicine and chalcone 3d were determined by measuring the ATPase activity of rhTopoIIα-ATPase using the ADP-Glo™ Kinase Assay. Briefly, 8 μL of buffer (40 mM Tris–HCl pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA) was added to each well of a 384-well plate (Promega, solid white) with 5 μL of enzymes (10 ng/μL) and 2 μL of the test compound at different concentrations. The reaction was initiated by the addition of 5 μL of 12.5 μM ATP, allowed to proceed for 1 h at room temperature and then stopped by the addition of 5 μL of ADP-Glo™ Reagent and incubating at room temperature for 40 min. Next, 10 μL of Detection Reagent was added and incubated for 30 min prior to the addition of luciferase and luciferin to detect the ATP by measuring the luminescence of each well with a microplate spectrophotometer system (Synergy HTX Multi-Mode reader, BioTek, Winooski, VT). All assays were performed in triplicate. The percentage relative inhibition of salvicine and 3d was calculated as shown in Equation (1);

\[
\% \text{ relative inhibition} = \frac{(positive - negative) - (sample - negative)}{positive - negative} \times 100,
\]

where negative and positive are the luminescence without and with the enzyme activity, respectively, and sample is luminescence with the sample. Finally, the IC50 curve was determined by GraphPad Prism version 6 (GraphPad Sofware, La Jolla, CA).

3. Results and discussion

3.1. Molecular docking studies

To investigate the most favorable binding site of the 47 designed chalcones, each compound was separately docked into the ATP-binding site in the ATPase domain of hTopoIIα and the etoposide-binding pocket in the hTopoIIα/DNA complex. The predicted interaction energies of all chalcones at both sites were plotted and compared with those of salvicine and etoposide (Figure 3). The interaction energies of the chalcones ranged from −45.6 to −32.4 kcal/mol in the etoposide-binding pocket and from −60.0 to −37.5 kcal/mol in the ATP-binding site. This suggested that all the chalcone derivatives specifically interacted with the ATPase domain rather than with the hTopoIIα/DNA complex.

Among all 47 chalcones, the group-3 compounds (3c, 3d and 3f) showed high interaction energies with the hTopoIIα ATPase domain (−61.1, −60.7 and −59.3 kcal/mol), which were better than that of salvicine (−58.7 kcal/mol) at the hTopoIIα ATPase domain. However, none of the tested chalcones were stronger than etoposide binding in the hTopoIIα/DNA complex (−72.4 kcal/mol). Additionally, the mode of action of these three compounds was likely comparable with salvicine in the ATP-binding pocket.
The important residues that contributed to ligand stabilisation via van der Waals (vdW) and H-bond interactions are summarised in Table 1. There are at least four conserved residues between each chalcone and salvicine. The obtained results were similar to the docking study of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazidehydrochloride, and napthoquinone-containing compounds, which specifically targeted the ATPase domain\(^4\),\(^5\). Since \(^3\)c, \(^3\)d and \(^3\)f may be effective as ATP competitors at the ATP-binding site of the hTopoII\(^a\) ATPase domain, these three compounds were synthesised and their in vitro cytotoxicity towards three cancer cell lines was then tested.

3.2. Cytotoxicity towards cancer cell lines

After screening the potent chalcones for inhibition of hTopoII\(^a\) by molecular docking, the three compounds that exhibited better interaction energies than salvicine (\(^3\)c, \(^3\)d and \(^3\)f) were selected for synthesis to test their cytotoxicity on the HT-1376, HeLa and MCF-7 cancer-derived cell lines using the MTT assay. The derived IC\(_{50}\) values of the three chalcone derivatives and salvicine on the three cancer cell lines are summarised in Table 2. All three screened chalcones showed a higher cytotoxicity to all three cell lines than salvicine, with \(^3\)d being the most cytotoxic with an IC\(_{50}\) value of 10.8 ± 1.1, 3.2 ± 2.2 and 21.1 ± 6.3 \(\mu\)M against the HT-1376, HeLa and MCF-7 cell lines, respectively. The IC\(_{50}\) of salvicine in a lung cancer cell line (A549) was previously reported to be 18.66 \(\mu\)M\(^6\). The diversity of the cytotoxicity of these three chalcones could suggest that the position of the methoxy group on the B ring of the chalcones affected the cytotoxicity. The methoxy groups substituted at the R2, R3 and R4 positions were found to be most important in terms of anti-cancer activities. Moreover, the different IC\(_{50}\) values of the chalcone derivatives in each cancer cell line may reflect the different expression levels of hTopoII\(^a\) and proliferation rates between those cell lines\(^6\),\(^1\). Cells containing a high concentration of hTopoII\(^a\) are more sensitive to hTopoII\(^a\)-inhibiting drugs than cells containing a lower concentration of hTopoII\(^a\). Thus, these chalcones might

---

Table 1. Contact residues of the hTopoII\(^a\) ATPase domain for the binding of salvicine and three chalcones (\(^3\)c, \(^3\)d and \(^3\)f). The residues in bold format stabilise the ligand binding via H-bond interaction, while the conserved residues between each chalcone and salvicine are shown in underlined format.

| Compound  | Structure | Contact residues |
|-----------|-----------|-----------------|
| Salvicine  | ![Salvicine](https://via.placeholder.com/150) | N91, S148, S149, R162, G164, A167 and K168 |
| \(^3\)c   | ![Chalcone 3c](https://via.placeholder.com/150) | N91, R98, G164, G166, A167 and K168 |
| \(^3\)d   | ![Chalcone 3d](https://via.placeholder.com/150) | N91, D94, T147, S148, S149, N150, G166 and K168 |
| \(^3\)f   | ![Chalcone 3f](https://via.placeholder.com/150) | N150, G164, A167, AT07 and K168 |

---

Figure 4. Superimposed structures of the three most active chalcones (\(^3\)c, \(^3\)d and \(^3\)f) from the docking study with that of salvicine in the ATP-binding pocket of the hTopoII\(^a\) ATPase domain. Figure created by NGL viewer (http://nglviewer.org/ngl/).
inhibit HeLa cells better than MCF-7 and HT-1376 cells because of the higher hTopoIIα levels typically expressed in cervical cancer cells than in breast and urinary bladder cancer cells. Considering the data from the in silico molecular docking and the in vitro cytotoxicity against cancer cell lines, it is possible that 3d tends to inhibit the hTopoIIα ATPase domain in a somewhat similar manner as salvicine. However, to gain additional information about the inhibition of hTopoIIα at the ATPase domain by salvicine and 3d, their in vitro inhibitory activity against the ATPase activity of rhTopoIIα was evaluated.

### 3.3. Inhibition of the hTopoIIα ATPase domain

In order to assess the inhibition of ATPase activity by salvicine and 3d, the rhTopoIIα ATPase domain was expressed from the pET28b-expression vector and enriched by following a previously reported protocol for use in the ATPase enzymatic activity assay. The rhTopoIIα ATPase domain was enriched to apparent homogeneity, with the 45 kDa ATPase domain evident as a single band following SDS–PAGE resolution and Coomassie blue staining (Figure 5(A)). The ATPase inhibitory activity of different concentrations of salvicine and 3d was then comparatively studied using a commercial kit (ADP-Glo™ Kinase Assay, see also in material). The obtained IC₅₀ values of the three chalcone compounds and salvicine against the HT-1376, HeLa and MCF-7 cancer-derived cell lines and the rhTopoIIα ATPase domain.

| Compound | HT-1376 | HeLa | MCF-7 | IC₅₀ against rhTopoIIα ATPase domain (nM) |
|----------|---------|------|-------|------------------------------------------|
| 3c       | 46.1 ± 4.2 | 30.9 ± 1.3 | 38.6 ± 1.4 | N/T                                      |
| 3d       | 10.8 ± 1.1 | 3.2 ± 2.2 | 21.1 ± 6.3 | 7.5 ± 4.2                                |
| 3f       | 92.0 ± 1.8 | 21.2 ± 8.7 | 72.1 ± 3.8 | N/T                                      |
| Salvicine| 106.5 ± 4.7 | 70.1 ± 4.5 | >200     | 326.5 ± 6.6                              |

N/T: non-tested.

![Figure 5](image-url)  
**Figure 5.** (A) SDS–PAGE gel analysis of the enriched rhTopoIIα ATPase domain. Lane M: molecular weight marker of standard protein; Lane 1: enriched rhTopoIIα ATPase domain (45 kDa). (B, C) The IC₅₀ curves of (B) salvicine and (C) 3d against the ATPase activity of rhTopoIIα. Data are shown as the mean ±1 SD, derived from three independent experiments.

### 3.4. MD simulations

All-atom MD simulations were performed on the docked 3d/hTopoIIα complex with three different velocities for 80 ns to understand the structure and dynamics of 3d at the ATP-binding site of the hTopoIIα ATPase domain. Since the 3d binding patterns and interactions with hTopoIIα obtained from three different simulations were similar, the results presented here are taken from one representative simulation. The root mean square displacement (RMSD) plot in Supplementary Figure S1 showed that the 3d/hTopoIIα complexes had reached equilibrium by 50 ns. Herein, the snapshots taken from the last 10 ns were extracted for analysis in terms of the binding pattern and ligand–protein interactions as follows.

In order to elucidate the hTopoIIα ATPase residues important for 3d inhibition at the ATP-binding site, the per-residue decomposition free energy (ΔGresidue) was evaluated by the MM/PBSA approach using the 100 snapshots over the last 10 ns simulation. The results are given in Figure 6(A), where the binding orientation of 3d inside the ATP-binding pocket with the contour energy of residue contribution is drawn in Figure 6(B). The fingerprint in Figure 6(A) showed only residues 50–250 in chain A, while the rest of protein (chain A residues 29–49 and 251–405 plus all chain B residues) had no interaction with the ligand. The negative and positive ΔGresidue values represented the degrees of stabilisation and destabilisation for ligand binding, respectively.

From Figure 6(A), 10 residues preferentially stabilised 3d with an energy contribution lower than −1.0 kcal/mol: E87, D94, R98, I125, I141, S148, S149, G164, Y165 and K168. This implies that these residues probably play a crucial role in 3d binding to the ATPase domain. The free energy contributions of each key residue, decomposed to backbone and side chain as well as electrostatic (Eele + Gpolar) and vdW (Evdw + Gvnonpolar) terms, are plotted in Figure 7. Most of the important residues support the 3d binding via the vdW energy contribution, while E87, D94 and K168 residues likely presented the electrostatic contribution. The strongest energy stabilisation for 3d (−3.8 kcal/mol) came from the K168 residue. In contrast, it has been reported that the K168 was not interfere with salvicine binding and even destabilised some mansonone G compounds in the ATP-binding pocket. However, the observed binding patterns of 3d in this work are somewhat similar with salvicine (E87, I125 and I141) and mansonone G (D94, I125, I141 and G164) in our previous work.

The results also demonstrated that the 3d binding energy is mainly contributed from the side chains of the key residues (E87, D94, R98, I125, I141, S148, S149, G164, Y165 and K168).

#### Table 2. In vitro IC₅₀ values of the three chalcone compounds and salvicine against the HT-1376, HeLa and MCF-7 cancer-derived cell lines and the rhTopoIIα ATPase domain.

| Compound | HT-1376 | HeLa | MCF-7 | IC₅₀ against rhTopoIIα ATPase domain (nM) |
|----------|---------|------|-------|------------------------------------------|
| 3c       | 46.1 ± 4.2 | 30.9 ± 1.3 | 38.6 ± 1.4 | N/T                                      |
| 3d       | 10.8 ± 1.1 | 3.2 ± 2.2 | 21.1 ± 6.3 | 7.5 ± 4.2                                |
| 3f       | 92.0 ± 1.8 | 21.2 ± 8.7 | 72.1 ± 3.8 | N/T                                      |
| Salvicine| 106.5 ± 4.7 | 70.1 ± 4.5 | >200     | 326.5 ± 6.6                              |

N/T: non-tested.
D94, R98, I125, I141, S148, S149, G164, Y165 and K168), except for the S148, S149, G164 and Y165 residues where the ligand–protein interactions substantially come from their backbone contributions. The information was well supported by the formation of two strong H-bonds between the carbonyl group of 3d and the backbone nitrogen of S149 (92%) as well as the 3-methoxy group on its A-ring and the backbone nitrogen of G164 (80%), (see intermolecular H-bonds between 3d and hTopollx residues in Figure 8).

4. Conclusions

A series of 47 designed chalcones were screened in silico as potent anti-cancer agents by computational methods. Molecular docking of the chalcone derivatives relative to salvicine, a known inhibitor of hTopollx at the ATPase domain, suggested that the ATP-binding site of hTopollx ATPase domain serves as the target site for the considered chalcones. The three most active chalcones (3c, 3d and 3f) had interaction energies towards the ATPase domain that were stronger than that of salvicine. Compound 3d, containing 2,4-dimethoxy and 6-hydroxy groups on A ring and 3',4',5'-trimethoxy on the B ring, showed the highest in vitro cytotoxicity against the HT-1376, HeLa and MCF-7 cancer cell lines. Moreover, 3d inhibited the rhTopollx ATPase activity in vitro with an IC50 value some 43.5-fold lower than that for salvicine. From 80-ns MD simulations of the 3d/hTopollx complex, the key residues responsible for 3d binding via vdW and electrostatic interactions were E87, D94, R98, I125, I141, S149, S148, G164, Y165 and K168. The residue K168 exhibited the strongest energy stabilisation for 3d, while residues S149 and G164 formed

Figure 6. (A) Per-residue decomposition free energy of 3d/hTopollx complex and (B) the binding orientation of 3d inside the ATP-binding pocket of ATPase domain, drawn from the last MD snapshot.

Figure 7. (Top) Per-residue decomposition free energy of the 10 key residues (black) and their contribution from backbone (dark gray) and side chain (light gray). (Bottom) The vdW (EvdW + Gnonpolar) and electrostatic (Eele + Gpolar) energy contributions are given in black and gray lines, respectively.
two strong H-bond interactions with the carbonyl and 3-methoxy groups of 3d. In summary, the in silico and in vitro results suggested that 3d can serve as a lead compound for further anti-cancer drug development.

Acknowledgements

The authors would like to thank Robert Butcher for constructive criticism and English language improvement of the manuscript. K.S. thanks the Thailand Graduate Institute of Science and Technology [TGIST Grant No. TG550958052D], the 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund), and the Overseas Presentations of Graduate Level Academic Thesis from Graduate School. N.K. thanks the Center of Excellence in Materials Science and Technology, Chiang Mai University for financial support. P.W. thanks Chulalongkorn University. Through travel grants for a short research visit, this research was also supported by the ASEAN-European Academic University Network (ASEA-UNINET). The Computational Chemistry Center of Excellent, and the Vienna Scientific Cluster (VSC-2) are acknowledged for facilities and computing resources.

Disclosure statement

No potential conflict of interest was reported by authors.

Funding

This study was financially supported by the Thailand Research Fund [grant number RSA5980069].

References

1. World Health Organization (WHO). WHO cancer 2017. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/; 2017.
2. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969–73.
3. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338.
4. Hande KR. Topoisomerase II inhibitors. Update Cancer Ther 2008;3:13–26.
5. Heck M, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 1986;103:2569–81.
6. Wendorff TJ, Schmidt BH, Heslop P, et al. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol 2012;424:109–24.
7. Robinson MJ, Martin B, Gootz T, et al. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 1991;266:14585–92.
8. Clausen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 2003;100:10629–34.
9. Wu T, Wang Y, Yuan Y. Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus. Antiviral Res 2014;107:95–101.
10. Cai Y-J, Lu J-J, Zhu H, et al. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H$_2$O$_2$ generation and topoisomerase II inhibition. Free Radic Biol Med 2008;45:627–35.
11. Pastor N, Domínguez I, Orta ML, et al. The DNA topoisomerase II catalytic inhibitor merbaroone is genotoxic and induces endoreduplication. Mutat Res 2012;738:73–89.
12. Baviskar AT, Amrutkar SM, Trivedi N, et al. Switch in site of inhibition: a strategy for structure-based discovery of human topoisomerase IIz catalytic inhibitors. ACS Med Chem Lett 2015;6:481–5.
13. Fortune JM, Osheroff N. Merbaroone inhibits the catalytic activity of human topoisomerase Ialpha by blocking DNA cleavage. J Biol Chem 1998;273:17643–50.
14. Meng L-h, Zhang J-s, Ding J. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 2001;62:733–41.
15. Keshawani RK, Misra K. Prediction of binding site for curcuminoids at human topoisomerase IIz catalytic protein; an in silico approach. Curr Sci 2011;101:1060–5.
16. Meng L-h, Ding J. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin 2007;28:1460–5.
17. Hu C-X, Zuo Z-L, Xiong B, et al. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 2006;70:1593–601.
18. Abu N, Ho WY, Yeap SK, et al. The flavokawains: uprising medicinal chalcones. Cancer Cell Int 2013;13:102.
19. Haraguchi H, Ishikawa H, Mizutani K, et al. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorganic Med Chem 1998;6:339–47.
20. Akihisa T, Tokuda H, Ukiya M, et al. Chalcones, coumarins, and flavanones from the exudate of Angelica keiskei and Glycyrrhiza inflata. Biochem Pharmacol 2006;70:591–601.
21. Chopra PG. Chalcones: a brief review. Int J Res Eng Appl Sci 2016;6:173–85.
22. Won S-J, Liu C-T, Tsao L-T, et al. Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur J Med Chem 2005;40:103–12.
23. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007;42:125–37.
24. Mahapatra DK, Bharti SK, Asati V. Anti-cancer chalcones: structural and molecular target perspectives. Eur J Med Chem 2015;98:69–114.
40. Ma Y-C, Wang Z-X, Jin S-J, et al. Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinoline-containing compound against human DNA topoisomerase II ATPase domain: a molecular modeling study. J Mol Liq 2017;247:374–85.

41. Ma Y-C, Wang Z-X, Jin S-J, et al. Dual inhibition of topoisomerase II and tyrosine kinases by the novel bis-fluoroquinoline-containing compound against human DNA topoisomerase II ATPase domain: a molecular modeling study. J Mol Liq 2017;247:374–85.

42. Malehpetroci P, Chusuth P, Kungwan N, et al. Molecular recognition of naphthoquinone-containing compounds against human DNA topoisomerase II\(^{\text{a}}\) ATPase domain: a molecular modeling study. J Mol Liq 2017;247:374–85.

43. Dennington RD, Keith TA, Millam JM. GaussView 5.0. 8. Gaussian Inc. 2008.

44. Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012;52:1757–68.

45. Meeprasert A, Khuntawee W, Kamlungsa K, et al. Binding pattern of the long acting neuraminidase inhibitor lanaminivir towards influenza A subtypes H5N1 and pandemic H1N1. J Mol Graph Model 2012;38:148–54.

46. Meeprasert A, Hannongbua S, Rungrotmongkol T. Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. J Chem Inf Model 2014;54:1208–17.

47. Kaiyawat N, Rungrotmongkol T, Hannongbua S. Effect of halogen substitutions on DUOMP to stability of thymidylate synthase/duOMP/mTHF ternary complex using molecular dynamics simulation. J Chem Inf Model 2013;53:1315–23.

48. Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09 Revision A. 1. Wallingford (CT): Gaussian Inc.; 2009.

49. Duke R, Giese T, Gohlke H, et al. Amber 14. University of California: San Francisco, CA; 2014.

50. Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem 2004;25:1157–74.

51. Duan Y, Wu C, Chowdhury S, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003;24:1999–2012.

52. Olsson MH, Søndergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 2011;7:525–37.

53. Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Biol Chem 1983;259:926–35.

54. Ryckaert J-P, Cicotti G, Berendsen HJ. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327–41.

55. York DM, Darden TA, Pedersen LG. The effect of long-range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods. J Chem Phys 1993;99:8345–8.

56. Cabrera M, Simoens M, Falchi G, et al. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure–activity relationships. Bioorganic Med Chem 2007;15:3356–67.

57. Sangpheak W, Kicuntod J, Schuster R, et al. Physical properties and biological activities of hesperetin and naringenin in complex with methylated beta-cyclodextrin. Beilstein J Org Chem 2015;11:2763–73.

58. Boonyalai N, Sittikul P, Pradiphol N, Kongsakhup N. Biochemical and molecular docking studies of naphthoquinone derivatives on the ATCase domain of human topoisomerase II. Biochem Pharmacol 2007;68:1125–41.

59. Siwek A, Stączek P, Wujec M, et al. Antiproliferative and pro-apoptotic activities of 2{\textsuperscript{a}}- and 4{\textsuperscript{a}}-aminochalcones against tumor canine cells. Eur J Med Chem 2017;138:884–9.

60. Mahalabputr P, Chusuth P, Kungwan N, et al. Molecular recognition of naphthoquinone-containing compounds against human DNA topoisomerase II\(^{\text{a}}\) ATPase domain: a molecular modeling study. J Mol Liq 2017;247:374–85.
amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839–47.

62. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270:21429–32.

63. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665–97.

64. Järvinen T, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996;148:2073.

65. Zhou Z, Zwelling LA, Kawakami Y, et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999;59:4618–24.

66. McLeod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994;59:607–11.